{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-019026","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2026-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.781598+00:00","generated_at":"2026-05-15T09:54:02.670831+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arvinas reports Phase 1 ARV-102 shows >50% LRRK2 degradation in CSF in Parkinson's patients","bullets":["ARV-102 achieved approximately 50% or greater LRRK2 reduction in CSF across all doses (20–80 mg) by day 14, maintained through day 28.","Treatment was well tolerated; all adverse events were mild, with no serious adverse events, discontinuations, or deaths.","Endolysosomal and neuroinflammatory biomarkers (e.g., CD68, GPNMB) were reduced in cerebrospinal fluid.","Mean plasma half-life of ARV-102 was 68 hours; CSF exposure increased dose-dependently indicating brain penetration.","Company plans Phase 1b trial in progressive supranuclear palsy in Q2 2026, with potential registrational trial in late 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-019026","json":"https://secwatch.observer/filing/0001628280-26-019026.json","markdown":"https://secwatch.observer/filing/0001628280-26-019026.md","text":"https://secwatch.observer/filing/0001628280-26-019026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000162828026019026/0001628280-26-019026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000162828026019026/arvn-20260318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:54:02.670831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}